Trends in Diseases Reported on US Death Certificates That Mentioned HIV Infection,1996-2006

Abstract

Objective: We examined trends during 1996-2006 in diseases reported on death certificates that mentioned HIV infection. Methods: We analyzed multiple-cause mortality data compiled from all US death certificates with any mention of HIV to determine the annual percentages of deaths with various diseases. Results: Deaths reported with HIV during 1996-2006 decreased from 35 340 to 13 750. Standardized percentages of death certificates reporting AIDS-defining opportunistic infections also decreased: pneumocytosis (6.3% to 5.1%), nontuberculous mycobacteriosis (5.5% to 1.8%), cytomegalovirus (5.7% to 1.2%). Non-Hodgkin’s lymphoma rose from 4.8% in 1996 to 6.4% in 1997 and declined to 5.0% in 2001, while Kaposi’s sarcoma declined from 3.7% in 1996 to 1.7% in 2001; these AIDS-defining cancers had stable percentages after 2001. All other cancers increased during 1996-2006 (2.7% to 7.3%). The percentage of deaths with diseases not specifically attributable to HIV increased: liver disease (5.8% to 13.0%), kidney disease (7.9% to 12.0%), and heart disease (4.9% to 10.2%). Conclusion: Among deaths reported with HIV, the percentages reported with HIV-attributable diseases decreased, while the percentages reported with other diseases increased. Consequently, these other life-threatening diseases need more attention in the management of HIV-infected persons.

Keywords

HIV infection mortality death certificates causes of death

References

Palella FJ, Jr , Delaney KM , Moorman AC , et al. Declining morbidity & mortality among patients with advanced HIV. N Eng J Med. 1998;338(13):853-860.

Centers for Disease Control and Prevention. Surveillance for AIDS-defining opportunistic illnesses , 1992-1997. CDC surveillance summaries. MMWR Morb Mortl Wwkly Rep. 1999;48(SS2):1-22.

Detels R. , Tarwater P. , Phair JP , et al. Effectiveness of potent antiviral therapies on the incidenceof opportunistic infections before and after AIDS diagnosis. AIDS. 2001;15(3):347-355.

Detels R. , Munoz A. , McFarlane G. , et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV duration. JAMA. 1998;280(17):1497-1503.

Fleishman JA , Helinger FH Recent trends in HIV-related Inpatient Admissions, 1996-2000: a 7-state study. J Acquir Immune Defic Syndr. 2003;34(1):102-110.

Selik RM , Byers RH, Jr , Dworkin MS Trends in diseases on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr. 2002 ;29(4):378-387.

Israel RA , Rosenberg HM , Curtin LR Analytical potential for multiple cause-of-death data. Am J Epidemiol. 1986;124(2): 161-179.

World Health Organization. International Classification of Diseases: Manual of the International Statistical Classification of Disease, Injuries, and Causes of Death. 9th ed. Geneva: World Health Organization; 1977.

World Health Organization. ICD-10: International Classification of Diseases: Manual of the International Statistical Classification of Disease and Related Problems. 10th Revision. Geneva: World Health Organization; 1992.

10.

Murphy SL Deaths: final data for 1998. Natl Vital Stat Rep. 2000; 48(11):1-105.

11.

Centers for Disease Control and Prevention. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months, and for HIV infection and AIDS among children aged 18 months to <13 years-United States, 2008 . MMWR Morb Mort Wkly Rep. 2008;57(No.RR-10):9 (Appendix A). http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a2.htm. Accessed September 17, 2010.

12.

Mocroft A. , Brettle A. , Kirk O. , et al. Changes in the cause of death among HIV positive subjects across Europe: results from the Euro SIDA study. AIDS. 2002;16(12):1663-1671.

13.

Cohen MH , French AL , Benning L. , et al. Causes of Death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med. 2002;113(2): 91-98.

14.

Palella FJ, Jr , Baker RK , Moorman AC , et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study . J Acquir Immune Defic Syndr. 2006;43(1):27-34.

15.

Buchacz K. , Rangel M. , Blacher R. , Brooks JT Changes in the clinical epidemiology of HIV infection in the United States: Implications for the Clinician. Curr Infect Dis Rep. 2009;11(1): 75-83.

16.

Valdez H. , Chowdhry TK , Asaad R. , et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis. 2001;32(10): 1487-1493.

17.

Crum NF , Riffenburg RH , Wegner S. , et al. Comparisons of causes of death and mortality rates among HIV-infected persons. Analysis of pre-, early, and late HAART (Highly Active Antiretroviral Therapy Eras. J Acquir Immune Defic Syndr. 2006;41(2):194-200.

18.

Bedimo R. , Chen RY , Accortt NA , et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis. 2004;39(9):1380-1384.

19.

Chiasson MA , Berenson L. , Li W. , et al. Declining HIV/AIDS Mortality in NY City. JAIDS . 1999;21(1):59-64.

20.

McNaghten AD , Hanson DL , Jones JL , Dworkin NS , Ward JW Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. AIDS. 1999 ; 13(13):1687-1695.

21.

Lee LM , Karon JM , Selik R. , Neal JJ , Fleming PI Survival after AIDS diagnosis in Adolescents and adults during the treatment era, 1984-1997. JAMA. 2001;285(10):1308-1315.

22.

Couglas E. , Rougier JP , Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int. 2005;67(2):393-403.

23.

Crum-Cianflone N. , Quigley M. , Utz G. , Hale B. BK virus-associated renal failure among HIV patients. AIDS. 2007; 21(11):1501-1502.

24.

Bica I. , McGovern B. , Dhar R. , et al. Increasing mortality due to end stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis . 2001;32(3):492-497.

25.

Fiala M. , Murphy T. , MacDougall J. , et al. HAART drugs induce mitochondrial damage and intercellular gaps and gp 120 causes apoptosis. Cardiovasc Toxicol. 2004;4(4):327-337.

26.

Murcia JM , Boix V. , Merino E. , Manso MI , Portilla J. Drug toxicity or syndrome of immune restoration causing fulminant cirrhosis after HAART-induced recovery. Eur J Clin Microbiol Infect Dis. 2002;21(2):153-155.

27.

Sulkowski MS , Thomas DL , Chaisson RE , Moore RD Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1): 74-80.

28.

Seeff LB Natural history of Hepatitis C. Hepatology. 1997; 26(3suppl1):21S-28S.